For years the honest answer to "are foreign patients really being seen routinely in top Chinese hospitals?" was a collection of individual anecdotes. That changed this month. At the first International Medical Cooperation and Exchange Conference, held in Shanghai during the China International Import Expo, cited statistics drew a clearer picture: in 2025 China's key foreign-facing hospitals recorded 1.28 million international patient visits, a 73.6% rise from three years earlier, and of those, 413,000 patients had traveled to China specifically for medical care — up 63% year on year, as reported by Phoenix News.
The number itself is the news; the more useful story for a patient deciding where to get treated is what the new counting method reveals. When a health system starts reporting "came specifically for care" as its own category, it is telling you that this traffic is large and steady enough to be worth measuring — a service, not a favor. This guide explains which policy channels sit behind that growth, and which practical questions about appointments, medicines and pricing each channel actually changes for a foreign patient.
What the 63% figure does — and does not — tell you
The statistic was presented at a conference hosted by the Shanghai Global Innovative Medical Device Exhibition and Training Center and SPH Holding, so read it as a conference-cited figure rather than a permanent line in a national statistical release. The exact mix of hospitals, the definition of "international patient," and the relationship between total visits and "came specifically for care" will likely be refined as the reporting matures.
What is still worth taking away is the direction and the signal. A 63% year-on-year rise in border-crossing-for-treatment patients, sitting inside a broader 73.6% climb in international visits, points to something structural. China's leading tertiary hospitals have moved from occasionally accommodating a foreign patient to operating an outward-facing service line: registration routes, interpreter support, and a policy scaffolding to make repeat, planned care plausible. For a patient weighing whether to come, that shift matters more than any single percentage, because it is the difference between "this might work once" and "this is designed to work."
The framing you should carry forward is therefore not "China is cheap and growing," which is marketing, but "the system now expects me," which is operational. The rest of this article maps the policy channels that turn that expectation into something you can plan around, and the questions to ask before you book. If you are still orienting yourself overall, our complete guide to medical tourism in China covers the basics this piece assumes.
Three policy channels, and what each one actually changes
The growth did not happen in a vacuum. Two national decisions and one regional pairing now define how foreign-facing care is delivered, and each touches a different part of your experience as a patient — registration, medicines, or pricing.
The first is the September 2024 notice from the Ministry of Commerce, the National Health Commission and the National Medical Products Administration on expanding openness in the medical sector, followed in November 2024 by a four-department work plan for a pilot in wholly foreign-owned hospitals. The second is the long-running linkage between Shanghai and Hainan's Boao Lecheng International Medical Tourism Pilot Zone, which the conference materials pointed to as part of the same policy movement. The third is the China International Import Expo itself, where the conference was staged — a trade setting that increasingly doubles as a channel for bringing overseas drugs and devices toward Chinese use.
Here is how to read them as a patient rather than as a policy analyst.
| Policy channel | What it is about | What it can change for a foreign patient |
|---|---|---|
| Wholly foreign-owned hospital pilot | Foreign investors allowed to run whole hospitals in pilot regions | Where you can find care built around international workflows, and how service fees are structured |
| Expanded opening in the medical sector (Sept 2024 notice) | Wider foreign participation across medical services and devices | The range of institutions and partners able to offer you care; the pace at which new services appear |
| Boao Lecheng pilot zone | A special zone for importing and using overseas-authorized drugs and devices ahead of general approval | Access to certain newer medicines and devices before, or independent of, standard national availability |
| Import Expo (CIIE) linkage | A trade platform that connects overseas manufacturers to the Chinese market | How quickly an overseas product moves toward actual availability for patients |
The distinction that matters for your decision: none of these channels publishes a "foreign patient price." The wholly-foreign-owned pilot mainly shapes the service and pricing environment — private institutions set their own fees, which is precisely why a quoted package from one hospital is not comparable to another. Lecheng and the CIIE linkage mainly shape medicine and device access — they are the routes by which a drug already authorized elsewhere can reach a Chinese patient sooner. For a foreign patient, the first set of channels answers "where and at what price do I get seen"; the second answers "can the specific drug or technology I need actually be given here." Before you commit, treat these as two separate questions with two separate answers.
When a drug approved in China first becomes a real reason to come
The access question is no longer hypothetical. In a useful illustration of timing, the FDA approved pimicotinib (brand name Pimjetmi, filed by EMD Serono) for adults with symptomatic tenosynovial giant cell tumor on 10 November 2026 — a tumor that is often mistaken for an ordinary joint swelling. The pivotal MANEUVER trial, randomized 2:1 against placebo, reported an objective response rate of 56% versus 3.2%, with 91% of responders holding their response for at least six months and 77% for at least twelve; common side effects included itching, rash, facial and around-eye swelling, fatigue, nausea, headache and limb swelling, alongside raised enzyme levels on blood tests.
What makes this relevant to a patient considering China is the sequence. The same molecule was first approved for market anywhere in the world in China in December 2025, developed by the original Chinese sponsor. A US approval now adds a second regulatory endorsement to a drug that was already available on the Chinese side. For a smaller group of patients — those with hard-to-diagnose, low-incidence tumors where an original-developer drug exists in China before it exists at home — this changes the calculus: coming to China can mean access to an already-marketed original drug, and potentially more clinical-trial slots run by the originating company. This is the same logic behind oncology-specific access that we outline for patients comparing cancer treatment in China. It is a genuine reason for some patients, not a universal one, and eligibility still turns on your exact diagnosis and staging.
AI reads your scan: the question to ask before you trust it
The third piece of current news affects something far more patients touch than a niche tumor drug — the imaging and screening software that increasingly reads their scans. On 9 November 2026, China's regulatory inspection center issued a document setting out inspection key points for artificial-intelligence medical devices, to guide how the quality systems behind AI devices are checked. It follows a draft opened for comment in October 2026 and lands alongside fresh good-manufacturing requirements for device software taking effect from 1 November 2026.
The practical meaning for an international patient is concrete. AI-assisted imaging and pathology screening in China is moving from "this software holds a registration certificate" to "this software's quality system is inspected against a specific standard." That lets you ask better questions before you rely on an AI-assisted result. Instead of accepting a brochure that says "AI," you can ask whether the software holds a Class III registration certificate, whether that certificate is still within its validity period, and which institution actually deployed it. A hospital that uses registered, inspected AI is a different proposition from one that markets it. If you are arranging imaging or a broader assessment during your trip, this is one of the things to clarify when you book a hospital appointment in Shanghai, where the mix of AI-enabled services varies most between institutions.
A decision checklist before you commit
Pulling the news and the policy together, the question is not "is China growing as a destination" — the 63% figure answers that — but "is it right for my specific situation." Work through this in order:
- Access, not price, first. Is the drug, device or procedure you need actually obtainable here now? For newer oncology molecules and certain technologies, the Lecheng and CIIE channels are the difference between "yes" and "not yet." Confirm this before anything else.
- Then the service line. Will you be seen through an international department or a foreign-facing pilot institution, and what does that do to fees, scheduling and interpreter support? A package from one institution is not a benchmark for another.
- Then the evidence chain. For AI-assisted or device-dependent steps, ask the registration and deployment questions above rather than trusting the word "AI."
- Then the logistics. Entry status, a realistic treatment window and a follow-up plan back home. Our China medical visa guide covers the entry side; the hospital directory and health-checkup options cover where and what.
A responsible caveat belongs in this section, not buried at the end: nothing here predicts an outcome for you. China's approvals, its pilot zones, and its inspection standards tell you what can be offered under regulation; they say nothing about what is appropriate for your body. Your specific treatment plan must be assessed in person by a licensed physician who has reviewed your actual records, imaging and history.
Where to start with OriEast
If you are past general curiosity and at the "should this be my destination" stage, the most useful next step is not a quote but a structured read of your case. OriEast helps international patients with translation, hospital registration and end-to-end coordination across Chinese hospitals, and can point you toward the access and service channels that fit your condition rather than a single institution.
Submit your records for a case evaluation so a clinician-facing review can tell you whether China genuinely offers you access worth traveling for, or whether you are better served elsewhere. If you have questions first, start an inquiry and we will map the practical path — appointments, medicines, interpreter support and pricing — before you spend anything on a trip.